List of Excipients in Branded Drug ESMOLOL HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	ACETIC ACID
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	HYDROCHLORIC ACID
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	SODIUM ACETATE
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	SODIUM CHLORIDE

Generic Drugs Containing ESMOLOL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	esmolol hydrochloride	0404-9785	ACETIC ACID
Henry Schein Inc	esmolol hydrochloride	0404-9785	HYDROCHLORIC ACID
Henry Schein Inc	esmolol hydrochloride	0404-9785	SODIUM ACETATE ANHYDROUS
Henry Schein Inc	esmolol hydrochloride	0404-9785	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in ESMOLOL HYDROCHLORIDE?

# Of NDCs	Excipient
20	ACETIC ACID
20	HYDROCHLORIC ACID
16	SODIUM ACETATE
4	SODIUM ACETATE ANHYDROUS

Esmolol Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Esmolol hydrochloride is an established, short-acting intravenous beta-1 blocker used in acute-care settings. Its commercial opportunity is concentrated in hospital formulations rather than chronic outpatient therapy. The strongest product strategies are ready-to-use presentations, high-concentration infusions, improved container systems, low-sodium options, and supply reliability.

The active ingredient has no meaningful remaining composition-of-matter exclusivity in the United States. Commercial differentiation must therefore come from formulation performance, regulatory execution, packaging, manufacturing efficiency, and hospital purchasing economics. Esmolol hydrochloride is a small molecule, so biosimilar risk does not apply.

What is esmolol hydrochloride used for?

Esmolol hydrochloride is an intravenous, cardioselective beta-adrenergic blocker with an approximate elimination half-life of nine minutes. Rapid onset and rapid offset allow clinicians to titrate the effect during short procedures and unstable acute-care episodes.

U.S. labeling identifies uses that include:

• Short-term control of ventricular rate in supraventricular tachycardia and atrial fibrillation or atrial flutter
• Control of tachycardia and hypertension during the perioperative period
• Short-term control of ventricular rate in noncompensatory sinus tachycardia where rapid titration is required

The drug is administered by continuous intravenous infusion, generally with a loading dose followed by a maintenance infusion. The short half-life creates a practical advantage over longer-acting beta blockers when clinicians need rapid adjustment or discontinuation.[1]

What therapeutic settings drive demand?

Demand comes primarily from:

Care setting	Use case	Commercial implication
Emergency departments	Acute tachyarrhythmia and rate control	Preference for rapid preparation and reliable availability
Intensive care units	Titrated heart-rate or blood-pressure control	Demand for infusion-ready products
Operating rooms	Perioperative tachycardia and hypertension	Value placed on low preparation time and pump compatibility
Cardiac units	Supraventricular tachycardia and atrial fibrillation	Need for predictable concentration and dosing
Interventional cardiology	Controlled heart-rate reduction	Small-volume, high-concentration formats may reduce fluid load

Esmolol is not a chronic oral beta-blocker substitute. The addressable market is linked to acute-care utilization, procedure volume, hospital formularies, and shortages of competing injectable agents.

What excipients are used in esmolol hydrochloride injections?

Commercial esmolol hydrochloride injections commonly use a simple aqueous buffer system. Representative U.S. labels identify sodium acetate, glacial acetic acid, and Water for Injection as inactive ingredients.[1,2]

Excipient	Primary function	Formulation relevance
Sodium acetate	Buffer component and pH control	Helps maintain a low, stable pH
Acetic acid	Acidifying agent and buffer component	Supports pH adjustment and drug stability
Water for Injection	Vehicle	Required for parenteral administration
Sodium chloride, where applicable	Isotonicity adjustment and diluent	May be present in premixed presentations
Nitrogen or other headspace control, where used	Oxygen reduction	May support stability of the packaged solution

The exact excipient profile depends on the dosage form and manufacturer. Concentrates, pharmacy-diluted products, and ready-to-use premixed bags may not have identical inactive ingredients.

Why is the formulation acidic?

Esmolol hydrochloride products are generally formulated at an acidic pH, commonly within approximately pH 4.5 to 5.5 depending on the product. The acetate/acetic acid system supports pH control and aqueous stability.

A low-pH formulation can create several development constraints:

• Compatibility with infusion lines and administration sets
• Local tolerability if extravasation occurs
• Chemical stability after dilution
• Container-closure compatibility
• Adsorption or interaction with tubing and filters
• Safe mixing with other intravenous medicines

The formulation objective is not simply to maximize pH. A higher pH may improve local tolerability in some circumstances but can reduce chemical stability or increase degradation risk. Any pH change would require new stability, compatibility, and clinical-use support.

What excipient strategies can differentiate esmolol hydrochloride products?

The most defensible excipient strategy is incremental improvement around an established acetate-buffered solution. A new product should reduce preparation burden, minimize administration risk, or improve storage and compatibility.

Ready-to-use formulations

Ready-to-use bags eliminate pharmacy dilution of concentrated esmolol. This can reduce compounding steps, calculation errors, and time to administration.

Commercial formats may include:

• 10 mg/mL infusion bags
• 20 mg/mL high-concentration bags
• Small-volume vials for bolus or pump preparation
• Dual-chamber or pharmacy-activated systems
• Standardized concentrations compatible with smart infusion pumps

Ready-to-use products are particularly attractive in emergency and operating-room settings, where preparation speed has direct operational value.

High-concentration formulations

A higher concentration can reduce total fluid volume. This matters for patients with heart failure, renal impairment, pulmonary edema, or fluid restrictions.

The tradeoffs include:

• Greater risk of dosing error
• Need for concentration-specific labeling
• Pump-library integration
• More demanding extractables and leachables assessment
• Potentially different compatibility behavior
• Higher consequence of an infusion-rate mistake

A high-concentration product should use a distinct presentation, color coding, barcoding, and dosing instructions to reduce selection errors.

Low-sodium or sodium-free options

Sodium acetate and sodium chloride contribute to total sodium exposure. A low-sodium formulation could have value in fluid-restricted or sodium-sensitive patients, although the sodium contribution from typical esmolol dosing may be modest compared with the broader clinical context.

Potential approaches include:

• Lowering sodium acetate while preserving buffer capacity
• Using an alternative buffer system
• Reducing formulation volume through concentration increase
• Providing a sodium-free concentrate for controlled pharmacy dilution

Alternative buffers create regulatory and technical risk. Histidine, citrate, phosphate, or other buffers could alter pH stability, compatibility, osmolality, and degradation pathways. The existing acetate system has a substantial development and commercial advantage because it is familiar to regulators and hospital pharmacists.

Preservative-free packaging

Preservative-free single-dose vials and infusion bags are appropriate for intravenous acute-care use. A preservative-free presentation reduces concerns about repeated-dose contamination and avoids unnecessary excipient exposure.

The main opportunity is packaging rather than adding a new excipient. Terminally sterilized, single-use containers and robust container-closure integrity can support a clean label and broad hospital acceptance.

Premixed dilution media

Esmolol can be supplied in an infusion-compatible diluent, such as sodium chloride injection, where the product is designed and labeled for that vehicle. The commercial benefit is removal of a separate dilution decision.

A premixed product must demonstrate:

• Stability through labeled shelf life
• Stability after opening or spiking, where relevant
• Compatibility with standard administration sets
• Resistance to leakage and port failure
• Acceptable overfill and delivery accuracy
• Performance under refrigerated and room-temperature conditions

The most valuable premix is not necessarily the product with the most excipients. It is the product that fits hospital workflow with minimal preparation and low waste.

What formulations are protected by esmolol hydrochloride patents?

The core esmolol hydrochloride molecule and the original injectable product were developed decades ago. U.S. composition-of-matter and original-product exclusivity have expired. Current commercial barriers are therefore unlikely to arise from the active ingredient itself.

Potential formulation protection could cover:

• Specific acetate buffer concentrations
• Narrow pH ranges
• High-concentration aqueous solutions
• Premixed infusion compositions
• Stability after dilution
• Container-closure systems
• Low-sodium formulations
• Manufacturing processes that reduce impurities
• Use of particular infusion containers or administration sets

Such claims face a high obviousness risk when they cover routine optimization of pH, buffer concentration, tonicity, or packaging. A stronger patent position would require unexpected stability, compatibility, shelf-life, or clinical-use results.

How strong is the patent estate for esmolol hydrochloride?

The estate is weak for the active ingredient and conventional injectable formulation. A new entrant should assume:

1. No practical composition-of-matter barrier.
2. Limited value in relying on broad claims covering esmolol hydrochloride solutions.
3. Greater value in narrow, data-supported formulation or device claims.
4. A need to compete primarily through manufacturing cost, supply reliability, and hospital contracting.

Patent value increases if a formulation solves a documented problem, such as precipitation after dilution, loss of potency in a particular container, reduced adsorption to tubing, or materially longer in-use stability.

When does esmolol hydrochloride lose exclusivity?

Esmolol hydrochloride lost U.S. regulatory exclusivity and original patent protection many years ago. The reference product, Brevibloc, was approved by the FDA in the 1980s, and generic injectable products have been marketed for years.[1,3]

Exclusivity category	Status
New chemical entity exclusivity	Expired
Original composition-of-matter patent	Expired
Original injectable formulation protection	Expired or no longer commercially blocking
U.S. pediatric exclusivity	No current relevance
Orphan-drug exclusivity	Not applicable to the conventional product
Biosimilar exclusivity	Not applicable
Current generic entry barrier	Primarily regulatory, manufacturing, and commercial

Exact patent expiry dates for historical patents have limited commercial relevance because the product has already experienced generic entry. A new developer should focus on current product-specific patents, if any, rather than the original drug patent.

What is the FDA regulatory status of esmolol hydrochloride?

Esmolol hydrochloride is an FDA-approved prescription intravenous drug. Generic versions may be submitted through the abbreviated new drug application pathway when they demonstrate pharmaceutical equivalence, bioequivalence where applicable, and compliance with quality requirements.

The main regulatory issues for an injectable esmolol product include:

• Sterility assurance
• Endotoxin control
• Particulate matter
• Assay and impurity limits
• pH and osmolality
• Container-closure integrity
• Extractables and leachables
• In-use and dilution stability
• Compatibility with administration systems
• Labeling of concentration and infusion rate

A conventional aqueous injectable is generally more straightforward than a novel delivery system. A new excipient or materially different buffer could increase the FDA review burden and require stronger toxicology and compatibility justification.

What is the Orange Book status of esmolol hydrochloride?

The reference product and generic injectable products are subject to the FDA’s prescription-drug approval framework. Because the original product is old and generic versions are marketed, Orange Book-listed patent protection is not the principal commercial issue.

Paragraph IV litigation is unlikely to be a central risk for a standard esmolol hydrochloride injection. A Paragraph IV certification could arise if a sponsor develops a product that references a listed patent, but the established market profile makes ordinary formulation patents more relevant to follow-on products than to the legacy active ingredient.

Which companies are challenging or competing with esmolol hydrochloride?

Competition exists at three levels: generic esmolol manufacturers, alternative intravenous beta blockers, and non-beta-blocker rate-control therapies.

Generic and hospital-supply competition

The market has included generic injectable suppliers and hospital-focused manufacturers. Supplier participation can vary by country, presentation, and shortage status. Contract manufacturers and distributors may also sell products under private-label arrangements.

The commercial differentiators are usually:

• Lowest delivered cost
• Reliable allocation
• Multiple vial and bag sizes
• Consistent national availability
• Shelf life
• Electronic ordering and barcode compatibility
• Ability to support hospital group purchasing contracts

Therapeutic competition

Product or class	Advantage versus esmolol	Limitation
Metoprolol injection	Familiar beta blocker and lower unit cost in some markets	Longer duration and less rapid titration
Labetalol injection	Combined alpha and beta blockade	Less beta-1 selectivity and longer effect
Diltiazem injection	Effective rate control in selected patients	Different contraindications and hemodynamic profile
Verapamil injection	Rate control in selected supraventricular arrhythmias	Greater risk in ventricular dysfunction or conduction disease
Landiolol, where marketed	Very short-acting beta-1 blockade	Limited geographic availability and premium pricing
Amiodarone injection	Broad antiarrhythmic use	Longer duration and distinct toxicity profile

Landiolol is the most direct technical comparator because it is also an ultra-short-acting beta-1 blocker in markets where it is approved. Esmolol retains an advantage in U.S. familiarity, generic availability, and established hospital use.

What commercial opportunities exist for esmolol hydrochloride?

Hospital workflow products

The highest-probability opportunity is a ready-to-use product that reduces preparation steps. A 10 mg/mL bag with standardized labeling can target emergency departments, operating rooms, and intensive care units.

A premium may be justified if the product demonstrates:

• Reduced pharmacy preparation time
• Lower medication-waste rates
• Improved barcode scanning
• Stable supply during shortages
• Broad compatibility with infusion pumps
• Longer room-temperature shelf life

Fluid-restricted care

A concentrated product can target cardiac intensive care, perioperative care, and patients requiring tight fluid management. The product should be supported by clear dosing conversion tools and pump-library files.

Shortage-resistant supply

Esmolol is an acute-care medicine where stockouts can affect procedural and emergency capacity. A manufacturer with redundant API sourcing, domestic fill-finish capability, and multiple container sizes may capture contracts even without patent exclusivity.

Geographic expansion

Regulatory and commercial opportunities may exist in markets where:

• The reference product is unavailable
• Generic competition is limited
• Hospital use of short-acting beta blockers is increasing
• Premixed IV products are underdeveloped
• Local manufacturing is favored by procurement rules

The formulation should be adapted to local labeling, diluent standards, container requirements, and pharmacopoeial expectations. A U.S. formulation package does not automatically establish approval in Europe, Japan, China, or emerging markets.

Combination or delivery-system opportunities

Combination infusion systems may create commercial value, but fixed-dose combinations with other cardiovascular drugs would carry significant compatibility and safety risks. The more practical opportunity is an integrated delivery platform, such as:

• Pre-labeled infusion bags
• Pharmacy-ready syringes
• Smart-pump-compatible presentations
• Closed-system transfer devices
• Unit-dose emergency kits

These products may be protectable through device, packaging, or workflow patents rather than broad composition claims.

What manufacturing and intellectual-property barriers affect market entry?

The active ingredient is not the principal barrier. The significant barriers are sterile manufacturing, quality control, and hospital-scale supply.

Key technical risks include:

• Esmolol degradation during prolonged storage
• pH drift
• Container interaction
• Particulate generation
• Filter or tubing adsorption
• Incompatibility after dilution
• Sterility failures in high-volume bag production
• Supply interruption for sterile components

Manufacturing cost can be reduced through a standardized acetate-buffered platform, high-throughput filling, automated visual inspection, and common container components across multiple hospital products.

A differentiated patent portfolio should focus on verified technical results. Useful claim categories include formulation ranges, container systems, in-use stability, and manufacturing controls. Broad claims to esmolol hydrochloride in water or acetate buffer are less likely to provide durable protection.

What patent litigation and settlement risks exist?

The litigation profile is materially lower than for recently approved branded drugs. Esmolol hydrochloride has been genericized for years, and there is no biosimilar litigation pathway.

Potential disputes could involve:

• A novel high-concentration formulation
• A premixed infusion bag
• A device-enabled presentation
• A manufacturing process
• Trade dress or labeling
• Supply or distribution agreements

Settlement agreements are not a central feature of the legacy esmolol market. A new formulation sponsor should expect freedom-to-operate work to focus on current formulation, packaging, and device patents rather than historical Brevibloc patents.

How does esmolol hydrochloride compare with landiolol?

Esmolol and landiolol are both short-acting beta-1 blockers, but their commercial positions differ.

Attribute	Esmolol hydrochloride	Landiolol
Regulatory footprint	Broad U.S. generic presence	More limited, market-dependent
Formulation maturity	Established injectable platform	Opportunity for newer presentations
Patent position	Largely expired legacy estate	Potentially stronger in some jurisdictions
Hospital familiarity	High in the United States	Varies by market
Commercial pricing	Generic pressure	Potential premium where available
Development opportunity	Workflow, concentration, supply	Geographic expansion and formulation differentiation

Esmolol is better positioned for cost-sensitive hospital procurement. Landiolol may compete where clinicians value ultra-short beta-1 blockade and local reimbursement supports a premium.

What revenue exposure does esmolol hydrochloride create?

Public companies generally do not report esmolol revenue separately. Product-level revenue depends on contract pricing, geographic mix, shortage conditions, and whether the supplier sells branded, generic, or private-label products.

Revenue exposure is most relevant for:

• Hospital injectable manufacturers
• Generic companies with critical-care portfolios
• Contract manufacturers with sterile filling capacity
• Distributors holding government or group-purchasing contracts
• Companies exposed to injectable-drug shortages

The market is unlikely to support high branded pricing without a differentiated presentation. A profitable strategy requires low manufacturing cost, high utilization of sterile capacity, and reliable hospital contracting.

Key Takeaways

• Esmolol hydrochloride is an established intravenous beta-1 blocker with rapid onset and rapid offset.
• The standard formulation uses Water for Injection with sodium acetate and acetic acid as the principal excipients.
• Composition-of-matter and original-product exclusivity have expired.
• Biosimilar risk does not apply because esmolol hydrochloride is a small molecule.
• The strongest commercial opportunities are ready-to-use bags, high-concentration products, low-preparation presentations, and shortage-resistant supply.
• Formulation patents must rely on specific technical advantages because broad buffer and aqueous-solution claims face significant obviousness risk.
• FDA regulatory risk centers on sterile manufacturing, stability, compatibility, container closure, and labeling.
• Hospital workflow and supply reliability are more important commercial levers than conventional drug patent exclusivity.

FAQs About Esmolol Hydrochloride Excipients and Commercial Strategy

Does esmolol hydrochloride injection contain preservatives?

Common injectable products are formulated as preservative-free sterile solutions using sodium acetate, acetic acid, and Water for Injection. The inactive ingredients must be confirmed against the specific manufacturer’s label.

Can esmolol hydrochloride be formulated without sodium acetate?

Potentially, but replacing sodium acetate would require new stability, pH, osmolality, compatibility, and regulatory data. Sodium acetate is part of the established formulation platform.

Is a concentrated esmolol infusion commercially attractive?

Yes. A concentrated infusion can reduce fluid volume and pharmacy preparation, particularly in intensive-care and perioperative settings. The product requires strong dosing controls to limit concentration-selection errors.

Is esmolol hydrochloride subject to Paragraph IV challenges?

A standard generic product faces little practical Paragraph IV exposure because the original active-ingredient and product exclusivities are long expired. Paragraph IV issues could arise for a new formulation that references a later-listed patent.

Can esmolol hydrochloride receive new patent protection?

A new patent may be available for a non-obvious formulation, container, device, manufacturing process, or stability profile. Broad claims covering conventional esmolol hydrochloride solutions are less likely to provide strong protection.

References

1. U.S. Food and Drug Administration. (n.d.). Brevibloc (esmolol hydrochloride) injection prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Esmolol hydrochloride injection.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
4. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
5. National Center for Biotechnology Information. (n.d.). PubChem compound summary: Esmolol.